Corticosteroids - 16,17 Flashcards

(78 cards)

1
Q

Adrenal glands

  • the cortex produces ___, ___, and ___
  • the medulla produces ___ and ___
A
  • glucocorticoids, mineralcorticoids, and androgens
  • epinephrine and norepinephrine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Glucocorticoids

  • ___ hormones
  • increase circulating ___
  • potent ___ effects
  • ___ critical for selectivity
A
  • stress
  • glucose
  • anti-inflammatory
  • 17a-OH
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Mineralocorticoids

  • ___ retention
  • ___ blood volume
  • ___ blood pressure
A
  • Na+
  • increased
  • increased
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Contrasting modes of action of stress hormones - epinephrine

  • binds to B adrenergic receptor ___
  • initiated signal transduction ___
  • ___ response
  • breaks down ___ and release ___
  • fight or flight - ___ term
A
  • GPCR
  • cascade
  • immediate
  • glycogen, glucose
  • short
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Contrasting modes of action of stress hormones - cortisol

  • binds to ___ receptor (a ___ hormone receptor)
  • regulates gene transcription, translation, and ___ production
  • induced ___ term response
  • ___ gluconeogenic enzymes
  • ___ pro-inflammatory processes
A
  • glucocoricoid, nuclear
  • protein
  • long
  • induces
  • inhibits
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Regulation of glucocorticoid synthesis

  1. stress causes hypothalamus to release ___
  2. this triggers the pituitary gland to release ___
  3. this triggers adrenal gland to release ___ leading to physiological responses and a negative feedback loop
A
  • Corticotropin releasing hormone (CRH)
  • Adrenocorticotropic hormone (ACTH)
  • Cortisol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Regulation of mineralocorticoid synthesis

The anterior pituitary does not control the synthesis of ___
* When the pituitary gland is surgically removed in animals, ___ synthesis is not affected significantly.

A

mineralocorticoids
aldosterone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Renin-angiotensin-aldosterone system

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Hormone response elements

  • DNA-binding domains of activated ___ bind to specific DNA sequences
    called ___, upstream of steroid responsive genes.
  • Binding alters rate of ___.
  • Glucocorticoids up-regulate enzymes for ___ and ___ proteins.
  • ___ carboxykinase - catalyzes the rate limiting step of gluconeogenesis
  • lipocortin 1 - suppresses ___ which has a critial role in ___ synthesis
A
  • dimers, Glucocorticoid Responisve Elements (GRE)
  • trascription
  • gluconeogenesis, anti-inflammatory
  • PEP
  • phospholipase A2, eicosanoid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Mechanism of immunosuppression by glucocorticoids

  • activated glucocorticoid receptor (GR) binds to ___ and prevents binding of ___ to its response element
  • transcription of ___ genes are repressed
A
  • NFkB
  • cytokine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Physiologic effects

  • Liver: ___ gluconeogenesis and glycogen storage
  • Muscle: ___ protein degradation, ___ protein synthesis and sensitivity to insulin
  • Adipose tissues: ___ lipolysis, ___ sensitivity to insulin
  • Immune system: block synthesis of ___ (immunosuppression), inhbit production of ___ (anti-inflammation)
A
  • increased
  • promote, decreased
  • promote, decreased
  • cytokines, eicosanoids

Overall: increase blood glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Adrenal insufficiency

  • hypoadrenalism
  • ___ secretion of steroid hormones by the adrenal cortex
  • caused by destruction of cortex by ___ or atrophy (primary; ___’s disease)
  • decreased secretion of ___ due to diseases of ___ (secondary; no ___)
A
  • decreased
  • tuberculorsis, Addison’s
  • Adrenocorticotropin (ACTH)
  • anterior pituitary, hypoaldosteronism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Adrenal insufficiency

Addison’s disease symptoms
* extreme ___
* ___, nausea, vomiting
* ___ blood pressure - ___ only
* hyperpigmentation of the skin - ___ only
* depression

A
  • weakness
  • anorexia
  • low, primary
  • primary
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

T or F: Cessation of long-term systemic glucocorticoid therapy can lead to Cushing symptoms.

A

False; leads to Addisonian symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Types of adrenal insufficiency

Primary - adrenal defect
CRH:
ACTH:
Cortisol:
Aldosterone:

A

increase
increase
decrease
decrease

CRH and ACTH have no negative feed back

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Types of adrenal insufficiency

secondary - pituitary defect
CRH:
ACTH:
Cortisol:
Aldosterone:

A
  • increase
  • decrease
  • decrease
  • not affected
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

tertiary - hypothalamic defect
CRH:
ACTH:
Cortisol:
Aldosterone:

A
  • decrease
  • decrease
  • decrease
  • not affected
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Cushing’s disease

  • hyperadrenalism
    causes:
  • Tumors in the ___ (adrenal Cushing’s disease)
  • ___ production of ACTH due to pituitary carcinoma (pituitary Cushing’s disease)
  • Ectopic production of ACTH due to ___ carcinoma (ectopic Cushing’s disease)
A
  • adrenal cortex
  • increased
  • non-pituitary
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Symptoms
* increased protein ___ (easy ___, delayed wound healing, muscle ___) and ___ glucose levels
* osteoporosis
* opportunistic infections
* ___ therapeutic use of systemic glucocorticoids can lead to Cushing’s
symptoms.

A
  • catabolism, bruising, wasting, increased
  • long term
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

adrenal Cushing’s disease
CRH:
ACTH:
Cortisol:

A
  • decrease
  • decrease
  • increase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

pituitary Cushing’s disease
CRH:
ACTH:
Cortisol:

A
  • decreased
  • increased
  • increased
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

ectopic Cushing’s disease
CRH:
ACTH:
Cortisol:
ectopic ACTH:

A
  • decrease
  • decrease
  • increase
  • increase

ectopic ACTH is produced from cancer cells (suppress immune system)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Therapeutic uses of corticosteroids

  • ___ adrenal insufficiency - ___ disease
  • allergic reactions: insect stings and ___
  • ___ and autoimmune diseases: rheumatoid arthhritis, lupus, IBD, chronic hepatic
  • **asthma **
  • immunosuppressive
  • anti-cancer
A
  • primary, adrenal
  • angioedema
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Cortisol versus cortisone

  • oxidation of ___ to ketone inactivates glucocorticoids
  • catalyzed by 11B-hydroxysteroid dehydrogenase in the ___
  • ___ reaction
  • cortisone is as effective as cortisol when used ___
  • cortisone should not be used in patients with imparied ___ function
A
  • 11 hydroxyl
  • liver
  • reversible
  • systemically
  • liver
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
# Systemic corticosteroids short acting t1/2 = ___ * 2 examples
* 8-12 hours * hydrocortisone * cortisone
26
# Systemic corticosteroids Intermediate-acting t1/2 = ___ * 4 examples
* 12-36 hours * prednisone * prednisolone * methylprednisolone * triamcinolone | week long therapy
27
# Systemic corticosteroids long acting t1/2 = ___ * 2 examples
36-54 hours * dexamethasone * betamethasone
28
# Synthetic glucocorticoids Fludrocortisone * 9aF * greater ____ activity than hydrocortisone * really strong ___ activity. Used in ___ replacement therapy * intense Na+ retention leading to ___
* glucocorticoid * mineralcorticoid, aldosterone * edema
29
# Synthetic glucocorticoids Prednisone/prednisolone * Extra double bond between ___ * more potent ___ activity * reduced ___ activity * interconvertable by ___
* C1 and C2 * glucocorticoid * mineralcorticoid * 11B-hydroxysteroid dehydrogenase
29
# Synthetic glucocorticoids Methylprednisolone * ___a-methyl group * potency similar to ___ * reduced ___ activity
* 6 * prednisolone * mineralcorticoid
30
# Synthetic glucocorticoids Triamcinolone * 9a-F and ___a-OH * glucocorticoid activity similar to ___ * reduced ___ activity * ___ hydrophilcity * ___ oral bioavailability
* 16 * prednisone * mineralocorticoid * reduced * low
31
# Synthetic glucocorticoids Dexamethasone * ___a-methyl group * ___ lipophilicity * ___ receptor binding * significantly stronger effect. * increased stability in plasma * reduced ___ activity
* 16 * increased * increased * mineralocortioid
32
# Synthetic glucocorticoids Betamethasone * ___ of dexamethasone at 16 * has simialr properties as ___
* enantiomer * dexamethasone
33
# 21-esters * The hydroxyl group at 21 can be modified to an ___ to control the property of glucocorticoids. * Prodrugs activated through hydrolysis by ___ * acetate and butyrate: ___ lipophilicity and ___ action for injection * succinate: soluble, ___ hydrolysis * phosphate: ___ solubility, ___ hydrolysis by ___ (10 minutes), IV or IM for emergency conditions
* ester * esterases * increased, prolonged * slow (30-45 min) * increased, rapid, phosphatases | one method of prodrug activation is hydrolyzing its ester
34
# Structure-activity relationship summary * 1,2 double bond lead to a 5 fold ratio enhancement of ___ activity * 11___ required for full GR/MR activity * 21___, F, or Cl required for GR/MR activity; ester ___ must be hydrolyzed to ___ for max activity * 17___ required for GR acrivity * 16a or B-CH3 or O substituent decreases ___ activity * 9a-F or Cl enhances ___ and ___ potency. * 6a-CH3 or F enhances ___ ratio
* GR/MR * B-OH * OH, prodrug, OH * a-O * MR * GR, MR * GR/MR
35
# Mechanism of glucocorticoid action in asthma * Glucocorticoids do not directly __ airway smooth muscle; little effect on acute ___ * Glucocorticoids will not stop an asthma attack while it is happening because they are too ___. * effective in inhibiting airway ___ * modulation of ___ and ___ production * inhibition of ___ synthesis * Inhibition of accumulation of ___ cells in lung tissue * ___ vascular permeanility
* dilate, bronchoconstriction * slow * inflammation * cytokine, chemokine * eicosanoid * immune * decreased
36
# Mechanism of glucocorticoid action in asthma Inhaled glucocorticoids are used ___ to control asthma. * effects may be seen within ___; max improvement in may not occur until after ___ weeks of treatment. * ___ is a concern
* prophylactically * 1 week several * compliance
37
# Inhaled glucocorticoids Desired properties
* high potency * minimal systemic effects * prolonged action
38
# Inhaled glucocorticoids Solutions ___ lipophilicity * tight receptor binding * better tissue penetration * ___ action by forming poorly soluble ___ * low ___ bioavailability * rapid clearance (___ half life)
* High * prolonged, microcrystals * oral * short
39
# Triamcinolone acetonide (Azmacort) * acetonide is resistant to ___ * 8x more potent than ____ | Inhaled glucocorticoids
* hydrolysis * prednisolone
40
# Beclomethasone dipropionate (Vanceril, Qvar) * converted rapidly to 17-monopropionate by ___ * 14x more potent than ___ | Inhaled glucocorticoids
* hydrolysis * dexamethasone
41
# Flunisolide (Aerobid) * ___ absorption from nasal or lung tissue * rapid metabolism by the ___ * minimal systemic adverse effect with ___ therapy | Inhaled glucocorticoids
* rapid * liver * long term
42
# Budesonide (Pulmicort) * 1:1 mixture of epimers at 16,17 butylacetal * ___ topical uptale * low oral ____ * extensive ___ metabolism | Inhaled glucocorticoids
* faster * bioavailability * first pass
43
# Mometasone furoate (Asmanex) * ___ potency * rapid ___ of action * negligible ___ availability * ___ oral bioavailability (1%) | Inhaled glucocorticoids
* high * onset * systemic * low
44
# Fluticasone propionate (Flovent) * inactivated by hydrolysis of ___ * rapid ___ metabolism * highly ___ and insoluble * ___ potency * ___ absorption of GI * ___ topical uptake | Inhaled glucocorticoids
* thioester * first pass * lipophilic * high * poor * rapid
45
# Topical glucocorticoids Desired properties * ___ lipophilicity for fast absorption * ___ systemic effect * prolonged action * ___ analogues are usually potent topical glucocorticoids * Once absorbed through the skin, topical glucocorticoids are metabolized primarily in the ___ and excreted into the urine or in the bile.
* high * minimal * Halogenated * liver
46
T or F: Glucocorticoids with high potency are safest for chronic application.
False; low potency is safest is applied often | high potency should be used only for a short duration of treatment.
47
# Triamcinolone acetonide ___ potency | Topical glucocorticoid
high
48
# Fluocinonide ___ potency
high
49
# Betamethasone valerate ___ potency
medium
50
# 21-chlorocorticoids Substitution of a ___ atom for the 21-hydroxyl group greatly enhances ___ anti-inflammatory activity.
Chlorine, topical
51
T or F: Fluticasone propionate and mometasone furoate have only medium potency.
True
52
# Adverse effects of glucocorticoids Crossover mineralocorticoid activity * ___ and ___ retention * development of ___ * Correctable with ___
* Na+ and water * hypertension * selective synthetic glucocorticoids
53
# Adverse effects of glucocorticoids Metabolic effects (increased glucose production) * steroid myopathy - high doses over a period of time cause proximal muscle ___ * Reduced ___ growth in children. Premature ___ of epiphyseal junction
* wasting * long bone, closing
54
Osteoporosis * Pharmacological dose of glucocorticoids inhibit ___ * Can be prevented by ___
* osteoblasts * bisphosphonate
55
# Adverse effects of glucocorticoids Cushing's like effects - redistribution of ___ * moon face * buffalo hump Impaired glucose tolerance * hyperglycemia from ___ * decreased ___ response * may unmask diabetes ___
* faft * gluconeogenesis * insulin * mellitus
56
# Adverse effects of glucocorticoids ___ of immune system * increased susceptibility to infections (THRUSH) * ___ wound healing Gastrointestinal * greater ___ risk CNS * linked to ___ metabolism * euphoria * depression Cataracts
* suppression * impaired * peptic ulcer * glucose
57
# Adverse effects of glucocorticoids Adrenal insufficiency upon withdrawal (Addisonian crisis) * due to negative feedback on the ___ and ___ from prolonged glucocorticoid use * decreases in ___ release * hypotension, weakness, inability to withstand ___
* hypothalamus and pituitary * ACTH * stress
58
What is this?
Cortisol | glucocorticoid
59
What is this?
Aldosterone | mineralocorticoids
60
What is this?
Cortisone | inactive
61
What is this?
Fludrocortisone | Used in mineralocorticoids replacement therapy
62
What is this?
Prednisone
63
What is this?
Prednisolone
64
What is this?
Methylprednisolone
65
What is this?
Triamcinolone
66
What is this?
Dexamethasone
67
What is this?
Betamethasone | enantiomer of dexamethasone
68
What is this?
Triamcinolone acetonide (Azmacort) | inhaled/topical glucocorticoid
69
What is this?
Beclomethasone dipropionate | inhaled glucocorticoid
70
What is this?
Flunisolide | inhaled/topical glucocorticoid
71
What is this?
Budesonide (Pulmicort) | inhaled glucocorticoid
72
What is this?
Mometasone furoate | Inhaled/topical glucocorticoids
73
What is this?
Fluticasone propionate | Inhaled/topical glucocorticoid
74
What is this?
Betamethasone valerate | topical (medium potency)
75
What is this
Clobetasol propionate | 21-cholorocorticoid topical
76
What is this?
Halobetasol propionate | 21-cholorocorticoid topical
77
What is this
Halcinonide | 21-cholorocorticoid topical